Evaluation of the adverse effects of iomeprol.
The new non-ionic contrast medium iomeprol (Iomeron) 150/200/250/300/350/400 was tested in a non-selected patient population (n = 4811). The aim of the clinical testing, in a very diverse range of radiographical examinations, was to evaluate its tolerance. A high percentage of the patients showed risk factors such as allergic predisposition (22.0%), cardiovascular diseases (45.3%), and kidney disease (15.1%). In addition, high doses of the contrast medium were used, depending on the radiological problem. The proportion of patients over 70 was 19.5%. Iomeprol proved to be an extremely well tolerated nonionic contrast medium. With the exception of nausea, systemic side effects occurred in less than 1% of cases.
Schmiedel
E
E
Department of Clinical Development, Bracco-Byk Gulden GmbH, Konstanz, Germany.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D015901:Angiography, Digital Subtraction; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D017023:Coronary Angiography; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000503:physiopathology; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007479:Iopamidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010690:Phlebography; D012307:Risk Factors; D012867:Skin / Q000187:drug effects; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; C057937:iomeprol; D007479:Iopamidol